Jane Street’s Kymera Therapeutics KYMR Stock Holding History

Jane Street’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.82M	Sell	21,800 -1,200	-5%	-$95K	﹤0.01%	5284
2025 Q4	$1.79M	Buy	23,000 +11,200	+95%	+$756K	﹤0.01%	5021
2025 Q3	$668K	Sell	11,800 -12,600	-52%	-$568K	﹤0.01%	7214
2025 Q2	$1.06M	Buy	24,400 +10,000	+69%	+$344K	﹤0.01%	5495
2025 Q1	$394K	Buy	14,400 +5,900	+69%	+$215K	﹤0.01%	7301
2024 Q4	$342K	Buy	+8,500	New	+$384K	﹤0.01%	7521
2024 Q1	–	Sell	-12,600	Closed	-$321K	–	9683
2023 Q4	$321K	Buy	+12,600	New	+$225K	﹤0.01%	7499
2023 Q3	–	Sell	-15,200	Closed	-$349K	–	9043
2023 Q2	$349K	Sell	15,200 -13,600	-47%	-$390K	﹤0.01%	6892
2023 Q1	$853K	Buy	28,800 +13,700	+91%	+$442K	﹤0.01%	5318
2022 Q4	$377K	Buy	+15,100	New	+$403K	﹤0.01%	6630
2022 Q2	–	Sell	-11,800	Closed	-$499K	–	10340
2022 Q1	$499K	Sell	11,800 -108,200	-90%	-$4.57M	﹤0.01%	7487
2021 Q4	$7.62M	Buy	120,000 +65,000	+118%	+$3.79M	﹤0.01%	2241
2021 Q3	$3.23M	Buy	+55,000	New	+$3.19M	﹤0.01%	3515

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Jane Street's KYMR Position: Q1 2026 in Review

Jane Street opened a new position in Kymera Therapeutics (KYMR) in Q1 2026: 2,939 shares worth $245K. The stake represents ﹤0.01% of the portfolio and ranks #9676 among its holdings. This is a return to the name: Jane Street previously reported a position in KYMR as recently as Q1 2025.

Jane Street first reported a position in KYMR in Q4 2020 and has held it in 17 quarters since. The position peaked at $4.99M in Q4 2023. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Jane Street held 2,939 shares of Kymera Therapeutics worth $245K as of Q1 2026.
Kymera Therapeutics was a new Jane Street position in Q1 2026.
Kymera Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9676 holding.
Jane Street first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 17 quarters since.
Jane Street's Kymera Therapeutics position peaked at $4.99M in Q4 2023.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.